Minocyclin

Phase 3Small molecule

UUniversity of Southern California

Minocyclin is one of 115 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 3.

Indications

Total Trials

Active Trials

114

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive DisorderActive, not recruiting

Subarachnoid HemorrhageActive, not recruiting

Ischemic StrokeActive, not recruiting

Major Depressive DisorderPhase 3

Active, not recruiting

Subarachnoid HemorrhagePhase 2

Active, not recruiting

Ischemic StrokePhase 2

Active, not recruiting

Competition

Competitive Landscape

430 competitors in Ischemic Stroke

#DrugCompanyPhaseTrials

Minocyclin

UUniversity of Southern California

Phase 3

1 2

Proamatine

Takeda

Preclinical

2 3

Repatha

Amgen

Preclinical

2 4

Levaquin

WWim Janssens

Preclinical

3 5

Tylenol

KKenvue Brands

Preclinical

1 6

Xylocaine

CCitius Pharmaceuticals, Inc.

Preclinical

1 7

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 8

Statins

Sanofi

Preclinical

1 9

Urokinase

Mmedac GmbH

Preclinical

3 10

Actilyse

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Recruiting

Major Depressive Disorder

NCT05644301

Q4 2028

Phase 2Active, not recruiting

Subarachnoid Hemorrhage

NCT04876638

Clinical

Trials by Indication[1]

Subarachnoid Hemorrhage1 trial

Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)

Active, not recruiting·UUniversity of Southern California·Phase 2·NCT04876638·20 enrolled

Ischemic stroke1 trial

Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke

Withdrawn·SState University of New York at Buffalo·Phase 2·NCT05367362

Major Depressive Disorder1 trial

INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder

Recruiting·UUniversiteit Antwerpen·Phase 3·NCT05644301·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Minocyclin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Minocyclin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Minocyclin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Southern California company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Southern California

Minocyclin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2028

Trials by Indication[1]

Subarachnoid Hemorrhage1 trial

Ischemic stroke1 trial

Major Depressive Disorder1 trial

References

Drug Info

Quick Facts

Related News